2023年2月14日,

LongeVC加入自由生物科学的一轮融资Psychedelic-Powered精神卫生保健公司开创性的使用氯胺酮和其他化合物在旧金山下一代治疗——(业务线)——#心理健康——生物科技基金LongeVC投资致幻剂启动生物科学自由。由耶鲁大学教授约翰·克里斯托和PsyMed企业创始人迪娜Burkitbayeva,自由生物科学发展下一代疗法来治疗精神疾病。公司支持的其他迷幻药,生物技术和关注老年人的基金和投资者,包括马拉Kichikov。虽然许多迷幻药与休闲使用,越来越多的研究支持他们强大的治疗效果。其中一个是氯胺酮。克里斯托发现其抗抑郁作用,博士和他的临床工作和耶鲁大学研究发展詹森的Spravato Esketamine喷雾,这对难治性抑郁症患者获得FDA批准于2019年。“临床研究已经显示了如何在管理强大的致幻剂的难治性精神卫生条件,“自由生物科学联合创始人兼首席执行官蒂娜Burkitbayeva说。“我们正在利用他们的力量来提供新的,更有效的药物需要帮助的病人。”“更好的心理健康是必不可少的健康长寿和应被视为不可或缺的一部分生命延长议程,“LongeVC联合创始人和合伙人加里Zmudze说。“通过解决紧迫的心理条件,我们努力支持的智力和身体健康的生活。” About LongeVC LongeVC is an international venture capital firm investing in visionary biotech companies and founders. Focusing on seed and early-stage investment, LongeVC’s mission is to bring to market breakthrough biotech that will change lives and transform the nature of our health. Its portfolio companies are deploying AI to find new treatments for chronic illnesses, developing SaaS tools to accelerate life-changing medical research and more. Learn more about LongeVC portfolio companies and join the fund as an investor at www.longevc.com About Freedom Biosciences Freedom Biosciences is a clinical-stage biotechnology platform developing next-generation viable and efficacious ketamine and psychedelic therapeutics. The company was co-founded by Dr. John Krystal, Chair of the Department of Psychiatry at Yale University, and Dina Burkitbayeva, founder of PsyMed Ventures, alongside Hunter Bouchard and Morgan Springer. Freedom Biosciences launched from stealth in 2022 and is backed by MBX Capital, Village Global and PsyMed Ventures, among others. To learn more, visit: www.freedombio.co Contacts